Related Experiment Video
Updated: May 23, 2026
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Role of antithrombotic agents in heart failure
John G F Cleland1, Saqib Mumtaz, Luca Cecchini
1Department of Cardiology, Hull York Medical School (University of Hull), Castle Hill Hospital, Kingston-upon-Hull, East Riding of Yorkshire, England, UK. j.g.cleland@hull.ac.uk
Insights
For heart failure patients with atrial fibrillation, anticoagulants are recommended. However, for those in sinus rhythm, antithrombotic therapy is generally not advised, even with coronary artery disease, due to limited evidence of benefit.
Area of Science:
- Cardiology
- Thrombosis Research
- Clinical Evidence Synthesis
Background:
- Antithrombotic therapy is widely used in cardiac patients, but robust evidence of benefit is scarce in many clinical scenarios.
- Patients with heart failure frequently have coexisting vascular disease and atrial fibrillation, worsening their prognosis.
- Current guidelines recommend anticoagulants for heart failure patients with atrial fibrillation.
Purpose of the Study:
- To evaluate the evidence for antithrombotic therapy in patients with heart failure, particularly those in sinus rhythm.
- To guide clinical decision-making in 'evidence-light' situations regarding antithrombotic use.
- To highlight the need for further research and appropriate trial design in this area.
Main Methods:
- Review and synthesis of existing clinical evidence on antithrombotic therapy in heart failure.
- Analysis of prognostic factors including vascular disease and atrial fibrillation in heart failure patients.
- Discussion of comparative effectiveness and safety of different antithrombotic agents (aspirin, clopidogrel, warfarin).
Main Results:
- Anticoagulants are appropriate for heart failure patients with atrial fibrillation.
- For heart failure patients in sinus rhythm, even with coronary artery disease, antithrombotic agents should generally be avoided due to insufficient evidence of benefit.
- If treatment is deemed necessary, clopidogrel or warfarin may have less evidence of harm compared to aspirin.
Conclusions:
- The use of antithrombotic therapy in heart failure patients without atrial fibrillation remains an 'evidence-light' problem requiring more research.
- Randomized controlled trials are crucial for clarifying the role and comparator choice (standard of care vs. addition to standard of care) for antithrombotics in this population.
- Clinical practice should prioritize evidence-based recommendations, reserving antithrombotic use for clearly indicated conditions.
Abstract:
Despite a vast body of research on antithrombotic therapy for patients with cardiac disease, there are few clinical settings where robust evidence of their benefit exists. Patients with heart failure often have vascular disease and atrial fibrillation contributing to their poor prognosis. For patients with heart failure and atrial fibrillation, anticoagulants are appropriate. For patients with heart failure in sinus rhythm, the weight of evidence suggests that doctors should generally avoid using any antithrombotic agent even if the patient has coronary artery disease. If there is a compulsion to treat, then there is less evidence of harm with clopidogrel or warfarin than with aspirin, although most receive aspirin. More research is required for this "evidence-light" problem. For those with the opportunity, engaging with a randomized trial is clinically and scientifically appropriate. The dilemma for such studies is the comparator. Should it be against or in addition to "standard of care" or both?
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:30Heart Failure V: Medical Management
01:22Heart Failure VI: Adjunct Therapies
01:22Heart Failure Drugs: β-Blockers
01:26Heart Failure Drugs: Inotropic Agents
01:22Heart Failure Drugs: Diuretics